Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Esperion Therapeutics (ESPR) reported a Q4 loss of $0.10 per share, which was better than the Zacks Consensus Estimate of a $0.14 loss. This is an improvement from the $0.50 loss per share a year ago.
March 04, 2025 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion Therapeutics reported a Q4 loss of $0.10 per share, better than the expected $0.14 loss, and an improvement from last year's $0.50 loss.
The better-than-expected earnings report and improvement from the previous year are likely to positively impact ESPR's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100